US Edition
Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs
- A direct comparison study conducted in the U.S. And published on May 11, 2025, in a leading medical journal evaluated the effectiveness of Eli Lilly's Zepbound versus Novo Nordisk's Wegovy for weight loss.
- The study involving 751 overweight or obese participants with weight-related health issues but no diabetes was funded by Eli Lilly to compare dual- and single-hormone targeting drugs.
- Participants on Zepbound lost about 50 pounds or 20% of body weight, nearly 50% more than Wegovy users who lost 33 pounds or 14%, with waist reductions of 18.4 cm versus 13 cm.
- Nearly 32% taking Zepbound lost at least 25% of body weight compared to 16% on Wegovy, and side effects were mainly mild gastrointestinal issues causing slightly more Wegovy discontinuations.
- The findings, presented by lead author Dr. Louis Aronne at the European Congress on Obesity, could influence prescribing practices while confirming both drugs remain important obesity treatments.
217 Articles
217 Articles
This GLP-1 Is the Most Effective for Weight Loss, Study Says
A new study says that people who use tirzepatide lose more weight than people who use semaglutide Getty Stock image of a woman weighing herself.Tirzepatide is more effective than semaglutide for weight loss, according to a new study on GLP-1 medications The study was funded by Eli Lilly, the pharmaceutical company that manufactures tirzepatide, so "take that with a grain of salt," one expert saidTirzepatide, which reduces appetite and improves h…
PODCAST: CFRA's House Calls for Sun. May 11th, 2025
Eli Lilly has plastered a 'fat tax' on the Canadian market for their weight loss drug. Dr. Yoni Freedhoff joins the program with his reaction. Then, Dr. Dworkin opens the phone lines and reads your texts.
Coverage Details
Bias Distribution
- 60% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
